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Serum prealbumin is higher in peritoneal dialysis than in hemo- strongly with the serum level of albumin, and correlates
dialysis: A meta-analysis. at least as well as albumin does with other nutrition
Background. Although not widely appreciated, the reported markers in both hemodialysis (HD) and peritoneal dial-concentration of serum preabumin, like that of serum choles-
ysis (PD) [abstract; Koomen et al, Perit Dial Int 14(Suppl 1):terol, tends to be higher in patients on peritoneal dialysis (PD)
S32, 1994] [1–9]. Serum prealbumin also predicts survivalthan on hemodialysis (HD), despite the substantial loss of pro-
tein during PD. at least as well as does serum albumin in HD [1, 2, 5,
Methods. The mean difference in serum prealbumin was 9], although not quite as well as serum albumin in PD
quantified by meta-analysis of the mean differences found in [10, 11].
six cohorts with both PD and HD patients (set 1; N  639)
K/DOQI clinical outcome goals have been set for theusing a fixed-effects model, and meta-analysis of the mean
serum levels of both prealbumin (30 mg/dL) and albu-prealbumin values reported in 23 cohorts of unselected dialysis
patients on a single modality (set 2; 9 PD cohorts, 14 HD min (4.0 g/dL) [12]. It is well known that serum albumin
cohorts; N  12,256) using a mixed model. For comparison, concentration tends to be lower in PD than in HD
the mean difference in serum albumin concentration between [13, 14], probably due to the substantial peritoneal loss
PD and HD also was estimated in sets 1 and 2 using the same of albumin [15–19]. It is not surprising, therefore, that amethods.
serum albumin level of 4.0 g/dL or greater was achievedResults. In set 1, the mean prealbumin difference (PD-HD)
by 32% of HD patients but only 17% of PD patients inin the individual cohorts ranged from 3.6 to 14.7 mg/dL (P 
0.05 in five cohorts), and the weighted mean difference was a recent large national survey [20]. Although not widely
5.4 mg/dL (95% CI, 3.8 to 7.0 mg/dL). In set 2, weighted mean appreciated, PD also alters the serum level of prealbu-
prealbumin was 8.1 mg/dL (95% CI, 5.2 to 10.9 mg/dL) higher min. However, serum prealbumin, like serum choles-in PD than in HD in the entire data set, and 6.9 mg/dL (95%
terol, tends to be higher in PD than in HD [1, 9, 13,CI, 5.2 to 8.6 mg/dL) higher in a sensitivity analysis that ex-
14, 21], despite the loss of prealbumin and lipoproteinscluded two outlying HD studies. By contrast, weighted mean
serum albumin concentration was significantly lower in PD during PD [19, 22–24]. If PD induces a higher serum
than in HD in both sets 1 and 2; the mean difference was prealbumin level and lower serum albumin level com-
0.25 g/dL (95% CI, 0.14 to 0.36 g/dL) in set 1 and 0.28 g/dL pared to HD, clinical targets specific to PD for these
(95% CI, 0.14 to 0.42 g/dL) in set 2.
proteins may be required.Conclusions. Serum prealbumin level is approximately
The purpose of this study was to quantify the mean6 mg/dL higher in PD than HD, perhaps due to the stimulation
of hepatic synthesis by PD albumin loss, while serum albumin difference in serum prealbumin between PD and HD by
is approximately 0.3 g/dL lower in PD. Different reference performing a pooled analysis of mean serum prealbumin
ranges and clinical targets (such as, K/DOQI guidelines) are values in two sets of published reports. Set 1 comprised
needed for PD and for HD.
articles or abstracts that reported serum prealbumin in
cohorts containing both PD and HD patients, and set 2,
articles that measured prealbumin in unselected dialysis
The concentration of serum prealbumin is a useful patients on a single modality. For comparison, the mean
indicator of prognosis in patients on dialysis. It correlates difference in serum albumin between PD and HD also
was estimated in each of these data sets.
Key words: prealbumin, albumin, peritoneal dialysis, hemodialysis,
prognostic indicator, end-stage renal disease, kidney.
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cohorts with both PD and HD patients were included
in set 1, and articles reporting mean serum prealbumin in
cohorts of unselected dialysis patients on a single mod-
ality were included in set 2. Published articles that re-
ported serum prealbumin in dialysis patients were lo-
cated by searching PUBMED using “prealbumin” as the
search word. Additional set 1 studies published as ab-
stracts were identified by a manual search of the abstract
publications of the American Society of Nephrology
(1982 to 2001), and those of the International Society for
Peritoneal Dialysis and the Annual CAPD Conference
published in PD International between 1989 and 2001.
The analysis was limited to publications located through
the end of August 2001, reporting prealbumin concen-
tration in units of mg/dL; when multiple follow-up re-
ports were available on the same cohort, the earliest
publication was chosen. Assay methods for prealbumin Fig. 1. Serum prealbumin (SE) in patients treated with hemodialysis
and albumin were recorded when available. (HD; ) or peritoneal dialysis (PD; ) in six set 1 cohorts.
Six cohorts were selected for set 1 comprising 198 pa-
tients on PD and 441 patients on HD. In the first cohort,
the PD and HD experiences were reported in separate
weighing each diffi by the inverse of its variance (weighti),publications [1, 21]; the second [14], third [9], and fourth
using a method based on a fixed-effects model [40]. The[25] cohorts were each reported in single articles, and
homogeneity of the distribution of the differences aboutthe fifth and sixth were reported as abstracts (abstracts;
the grand mean was tested with a chi-square test [Q Koomen et al, op. cit.; Fassinger et al, Perit Dial Int
 weighti  (diffi  grand mean)2].12(Suppl 1): 116, 1992) Three set 1 cohorts reported the
The set 2 study means were examined using a mixedprealbumin assay used (nephelometry [1, 9, 21]; immuno-
model, with dialysis modality as a fixed factor, study asdiffusion [24]); serum albumin data were available in
a random factor, and the inverse of the variance of thefour cohorts (abstract; Koomen et al, op. cit.) [1, 14,
mean (N SD2) as study weight. For any set 2 study that21, 25], and the method used in one (bromcresol green
reported the mean values of prealbumin (or albumin) for[1, 21]). Twenty-three cohorts were selected for set 2,
subgroups only, we computed a single value for meanincluding nine PD cohorts comprising 490 patients
and a single pooled SD value by combining the subgroup(range 8 to 147) [11, 19, 24, 26–31], and fourteen HD
data. The results of the meta-analysis presented are thecohorts comprising 11,766 patients (range 17 to 7123)
estimates of the mean (SE) in the PD and HD studies[2–7, 32–39]. The prealbumin assays used were report-
and of the mean difference. Sensitivity analyses wereed in eighteen studies and did not significantly differ
performed in order to test the robustness of the resultsbetween PD and HD (PD, immunodiffusion 3, immuno-
relative to exclusion of potential outliers defined by aprecipitation 1, immunonephelometry 3; and HD, immu-
t statistic	3.5. Computations were performed using SASnodiffusion 3, immunoprecipitation 2; immunonephe-
version 8 (SAS Institute, Cary, NC, USA).lometry 4; antigen-antibody complex 2; P 	 0.64 by
chi-square). Twenty-two set 2 studies (all except refer-
ence 24) reported albumin data, and the method was RESULTS
available in eleven (PD, bromcresol green 2, immuno-
Prealbuminchemical 1; HD, bromcresol green 6, immunodif-
In set 1, the mean concentration of serum prealbuminfusion 2).
was higher in PD than in HD in each of the six cohorts,
Statistics and data analysis the difference ranging from 3.6 to 14.7 mg/dL (P  0.05
in 5 of the cohorts; Table 1 and Fig. 1). There was aFor each cohorti in set 1 (where i  cohort identifica-
direct correlation between the HD and PD study meanstion number, ranging from 1 to 6), we tabulated the mean
(Spearman correlation coefficient 0.81 P 0.05), whichvalues of serum prealbumin (or albumin), the standard
suggests that the calibration of the assays varied betweendeviation (SD), and the number of subjects (N) sepa-
the studies. The weighted mean difference between PDrately for PD and HD, and computed the absolute differ-
and HD was 5.4 mg/dL (95% CI, 3.8 to 7.0 mg/dL).ence of the means (diffi) and tested its significance by
The set 2 study means also showed a clear trend tothe t test, and, lastly, computed the weighted mean of the
six diffi values and the 95% confidence interval (CI), increased values in PD (Fig. 2), which was highly signifi-
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Table 1. Mean serum prealbumin in set 1 cohorts
PDa HDa
Cohort Mean  SD (N) Mean  SD (N) Differencea P valueb
1 30.48.0 (33) 26.56.4 (125) 3.9 0.005
2 32.29.5 (71) 28.69.3 (53) 3.6 0.038
3 379 (55) 3110 (192) 6 0.0001
4 46.07.5 (3) 31.38.9 (21) 14.7 0.013
5 4412 (28) 3510 (41) 9 0.002
6 40.89.9 (8) 35.02.6 (9) 5.8 0.12
a mg/dL
b t test
Fig. 3. Mean serum albumin plotted against mean serum prealbumin
in patients treated with HD () or PD () in four set 1 cohorts. The
numbers used to identify the cohorts are the same as in Table 1.
Fig. 2. Prealbumin (SE) in 14 HD studies (open symbols) and 9 PD
studies (filled symbols) in set 2. Triangles, squares, and circles represent
samples of 
100, 101-1000, and 	1000 patients, respectively. Data are
mean  SE.
Table 2. Weighted estimates of mean serum prealbumin in PD and
HD and of the difference in set 2 studies
PD (N) HD (N) PD-HD P value
40.71.2 (9) 32.70.8 (14) 8.11.4 mg/dL 104 Fig. 4. Mean serum albumin plotted against mean serum prealbumin
40.71.0 (9) 33.10.7 (13)a 7.61.2 mg/dL 104 in patients treated with HD (open symbols) or PD (filled symbols) in
40.80.9 (9) 33.90.1 (12)b 6.90.9 mg/dL 104 twenty-two set 2 studies. Triangles, squares, and circles represent sam-
ples of 
100, 101 to 1000, and 	1000 patients, respectively.N denotes the number of studies. Data are mean  SE.
a Sensitivity analysis, excluding the largest outlier (see text)
b Sensitivity analysis, excluding the two largest outliers (see text)
Albumin
Mean serum albumin was significantly higher in HDcant on meta-analysis (Table 2). The estimate of the pre-
than in PD in each data set on meta-analysis. Thealbumin difference was 8.1 mg/dL (95% CI, 5.2 to 10.9
weighted mean difference was 0.25 g/dL (95% CI, 0.14mg/dL) in the analysis of all twenty-three studies. Sensi-
to 0.36 g/dL) in set 1, and 0.28  0.07 g/dL (P 
 0.001)tivity analyses also were performed excluding one or
in set 2. Prealbumin and albumin serum levels are knownboth of the most extreme outlying values, derived from
to correlate directly within a group of dialysis patientstwo HD studies that were large and, hence, heavily
treated with a single modality. However, when the albu-weighted, that is, studies 1 (N  1618 [38]) and 3 (N 
min and prealbumin study means were plotted together,1053 [34]) in Figure 2. Eliminating both these studies
an inverse trend was evident between the dialysis modal-yielded a conservative, lower estimate of the mean preal-
bumin difference (6.9 mg/dL; 95% CI, 5.2 to 8.6 mg/dL). ities in each data set (Figs. 3 and 4).
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DISCUSSION suboptimal (each PD cohort mean satisfied the prealbu-
min target but none satisfied the albumin target), and,Meta-analysis of two sets of publications yielded simi-
similarly, that PD therapy is both better (higher prealbu-lar estimates of the effect of dialysis modality on serum
min) and worse (lower albumin) than HD. On the otherprealbumin level. The mean concentration difference be-
hand, if these differences are regarded as intrinsic to PD,tween PD and HD was 5.4 mg/dL in set 1 and 6.9–8.1
as we suggest below, then the laboratory reference rangesmg/dL in set 2. The mean effect of dialysis on serum
and clinical target values should be set accordingly. Toalbumin concentration was also similar in both study
be consistent in both HD and PD, the respective targetssets: 0.25 to 0.28 g/dL higher in HD.
should be set approximately 6 mg/dL higher for prealbu-The meta-analytic models accounted for the variation
min and approximately 0.3 g/dL lower for albumin inin study means caused by sampling error and dialysis
PD, with the exact target values varying by laboratory.modality, but it is important to consider how the results
The cause of the depression in serum albumin in PDmight be affected by other factors, such as publication
is presumably the peritoneal loss of albumin (4 to 6 g/day)bias, confounding, and study artifacts [41]. It is unlikely
[17, 19, 22, 23, 45], a high proportion of the amount ofthat publication bias affects the present analysis because
albumin normally synthesized (10 to 15 g/day) [46, 47].the included studies were neither conducted nor pub-
Consistent with this supposition, the rate of loss of albu-lished for reasons related to whether dialysis affects pre-
min (or total protein) in PD correlates inversely withalbumin concentration. Some of the variation between
serum albumin [15–18]. However, the cause of the in-studies may be the result of confounding by differences
crease in prealbumin concentration in PD is unknown.in patient characteristics. For example, sex, diabetes, and
In fact, PD might be expected to lower serum prealbuminproteinuria may influence serum prealbumin (abstract;
because the rate of peritoneal loss of prealbumin (50 toMaru et al, J Am Soc Nephrol 8:72A, 1997) [1, 42, 43].
110 mg/day) [19, 24] represents a sizable fraction of theTo minimize this problem, set 2 included no cohorts that
normal synthesis rate (500 to 650 mg/day) [47]. There-had been assembled based on any of these characteristics
fore, the increased prealbumin level in PD must be due
(for example, all non-diabetics). Given the specificity of
to some combination of reduced volume of distribution,
immunoassays, it is unlikely that an interferent exists in increased rate of synthesis, and/or decreased rate of cata-
the serum having differing activities in PD and HD. bolic clearance in PD compared to HD. Prealbumin and
However, assay calibration differences will inevitably albumin normally have similar volumes of distribution
exist between studies [44]. They result in a spurious in- [47]. Even if there were systematic differences between
crease in the variation among the study means, and pre- PD and HD in the factors that influence distribution
sumably explain the direct correlation observed between volume, that is, capillary permeability and state of hydra-
HD means and PD means in set 1. Since the assay meth- tion, they would be unlikely to selectively raise the con-
ods for PD and HD were identical within each set 1 centration of prealbumin and not that of albumin be-
study, the impact of calibration on the estimate of the cause of the similarity of the two molecules in size and
concentration difference between PD and HD should charge [48]. One plausible, though speculative mecha-
be minimized. In set 2, the similarity of the assays used nism for the increase in serum prealbumin in PD is a
in the PD and HD studies also should reduce the impact change in the metabolism of prealbumin (increased he-
of calibration on the estimate of the difference, unless, patic synthesis or reduced systemic catabolism) due to
by chance, a large weight were assigned to an outlying peritoneal loss of a regulatory molecule (such as, albu-
value, which in fact occurs in this data set. This problem min), similar to the known alteration in cholesterol me-
was addressed in the sensitivity analysis that excluded tabolism. Observations in PD patients that support a
the two most extreme such outliers, producing a result causal role for albumin in regulating hepatic metabolism
(6.9 mg/dL) close to that of the set 1 analysis. Finally, any of other proteins or lipoproteins include: (a) the perito-
inflation of the variance, due to interstudy differences in neal rate of loss of albumin (or total protein) correlates
either patient or assay characteristics, widens the confi- directly with the elevation in serum cholesterol [15, 45];
dence intervals of the estimated difference. and (b) intravenous albumin infusion causes the serum
One implication of these concentration differences is levels of fibrinogen, factor 7, and lipoprotein(a) to fall
that the use a single value for either serum prealbumin [18]. Moreover, in nephrotic patients with normal renal
(30 mg/dL) or albumin (4.0 g/dL) as a clinical target function, it has been analogously found that the serum
[12, 20] is confounded by dialysis modality. A single tar- levels of prealbumin and cholesterol are both elevated,
get value would not be expected to perform consistently despite overt losses of prealbumin and lipoproteins, and
in both PD and HD. For example, using these targets to it has been hypothesized that, like serum cholesterol,
classify the prognosis and nutritional state of the cohorts serum prealbumin is elevated as a result of the stimula-
contained in sets 1 and 2 combined (Table 3) might lead tion of hepatic synthesis by the large renal loss of albumin
and/or the resultant hypoalbuminemia [43, 48, 49]. Fu-one to conclude that PD therapy is both optimal and
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Table 3. K/DOQI outcome goals for serum levels of prealbumin
and albumin applied to mean values from sets 1 and 2
Mean PD HD P valuea
Prealbumin 30 mg/dL 100% (15/15) 75% (15/20)b 0.048
Albumin 4 g/dL 0% (0/12) 39% (7/18) 0.016
a One-tailed Fisher’s exact test
b For the 18 HD cohorts that had serum albumin data, this rate is 72% (13/18)
targets should be set for PD and for HD, with the exact
values varying by laboratory.
Fig. 5. Proposed bimodal distribution of prealbumin and albumin se-
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